Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1902 1
1942 2
1943 1
1945 2
1946 9
1947 17
1948 21
1949 19
1950 24
1951 13
1952 19
1953 19
1954 17
1955 17
1956 24
1957 28
1958 27
1959 28
1960 11
1961 11
1962 32
1963 44
1964 40
1965 42
1966 44
1967 47
1968 30
1969 38
1970 30
1971 38
1972 26
1973 21
1974 31
1975 30
1976 47
1977 34
1978 40
1979 20
1980 32
1981 31
1982 20
1983 23
1984 18
1985 33
1986 35
1987 34
1988 30
1989 36
1990 40
1991 48
1992 38
1993 63
1994 48
1995 49
1996 60
1997 44
1998 50
1999 60
2000 42
2001 74
2002 51
2003 68
2004 78
2005 78
2006 66
2007 76
2008 96
2009 81
2010 97
2011 92
2012 106
2013 109
2014 115
2015 112
2016 132
2017 97
2018 103
2019 111
2020 113
2021 130
2022 100
2023 108
2024 106
2025 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,842 results

Results by year

Filters applied: . Clear all
Page 1
PICRUSt2 for prediction of metagenome functions.
Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower C, Langille MGI. Douglas GM, et al. Among authors: brown jr. Nat Biotechnol. 2020 Jun;38(6):685-688. doi: 10.1038/s41587-020-0548-6. Nat Biotechnol. 2020. PMID: 32483366 Free PMC article. No abstract available.
Differential diagnostic patterns of dysarthria.
Darley FL, Aronson AE, Brown JR. Darley FL, et al. Among authors: brown jr. J Speech Hear Res. 1969 Jun;12(2):246-69. doi: 10.1044/jshr.1202.246. J Speech Hear Res. 1969. PMID: 5808852 No abstract available.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR. Davids MS, et al. Among authors: brown jr. Blood. 2022 Feb 3;139(5):686-689. doi: 10.1182/blood.2021011386. Blood. 2022. PMID: 34788401 Free PMC article. Clinical Trial.
Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A, Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR. Tiao G, et al. Among authors: brown jr. Leukemia. 2017 Oct;31(10):2244-2247. doi: 10.1038/leu.2017.201. Epub 2017 Jun 27. Leukemia. 2017. PMID: 28652578 Free PMC article. No abstract available.
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS. Kwiatkowski N, et al. Among authors: brown jr. Nature. 2014 Jul 31;511(7511):616-20. doi: 10.1038/nature13393. Epub 2014 Jun 22. Nature. 2014. PMID: 25043025 Free PMC article.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Roberts AW, et al. Among authors: brown jr. N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6. N Engl J Med. 2016. PMID: 26639348 Free PMC article. Clinical Trial.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: brown jr. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Bannerji R, et al. Among authors: brown jr. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1. Lancet Haematol. 2022. PMID: 35366963 Free PMC article. Clinical Trial.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Woyach JA, et al. Among authors: brown jr. N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1. N Engl J Med. 2018. PMID: 30501481 Free PMC article. Clinical Trial.
3,842 results